论文部分内容阅读
目的对重组人B型利钠肽治疗扩张型心肌病心力衰竭患者的临床效果进行探讨分析。方法 80例扩张型心肌病心力衰竭患者作为本次研究的探讨对象,按照随机数字法将其分为对照组和观察组,每组40例。对照组患者给予常规治疗,观察组患者在对照组基础上给予重组人B型利钠肽治疗。对两组治疗情况进行对比分析。结果观察组患者治疗总有效率95.00%显著高于对照组的75.00%,差异具有统计学意义(P<0.05)。两组治疗前心功能各项指标比较差异无统计学意义(P>0.05)。治疗后观察组左室射血分数(LVEF)、左室舒张末期内径(LVEDd)均明显优于对照组,差异均具有统计学意义(P<0.05);治疗后两组左房内径(LAD)比较差异无统计学意义(P>0.05)。两组不良情况发生率比较差异无统计学意义(P>0.05)。观察组住院时间(7.69±2.76)d短于对照组(9.12±3.04)d,差异具有统计学意义(P<0.05)。结论临床治疗扩张型心肌病心力衰竭可采用重组人B型利钠肽治疗,其能有效提高治疗效果,且安全性高,具有较高的临床应用价值。
Objective To investigate the clinical effect of recombinant human B-type natriuretic peptide in patients with heart failure due to dilated cardiomyopathy. Methods 80 cases of dilated cardiomyopathy patients with heart failure as the object of this study, according to the random number method is divided into control group and observation group, 40 cases in each group. Patients in the control group were given routine treatment. Patients in the observation group were given recombinant human B-type natriuretic peptide on the basis of the control group. Comparative analysis of the two groups of treatment. Results The total effective rate of observation group was 95.00%, which was significantly higher than that of control group (75.00%), the difference was statistically significant (P <0.05). There was no significant difference between the two groups in the indexes of cardiac function before treatment (P> 0.05). The left ventricular ejection fraction (LVEF) and left ventricular end-diastolic diameter (LVEDd) in the observation group were significantly better than those in the control group after treatment (P <0.05) The difference was not statistically significant (P> 0.05). There was no significant difference in the incidence of adverse events between the two groups (P> 0.05). The length of stay in the observation group (7.69 ± 2.76) d was shorter than that in the control group (9.12 ± 3.04) d, the difference was statistically significant (P <0.05). Conclusion Clinical treatment of dilated cardiomyopathy heart failure can be treated with recombinant human B-type natriuretic peptide, which can effectively improve the treatment effect, and high safety, and has high clinical value.